Shetty Anirudh J, Singhal Manphool, Ramachandran Raja, Soundappan Kathirvel, Bhadada Sanjay K, Sudhayakumar Anand
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Department of Radiodiagnosis, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Endocrinol Metab. 2025 Jul-Aug;29(4):446-452. doi: 10.4103/ijem.ijem_502_24. Epub 2025 Aug 26.
Near-total parathyroidectomy (NPTX) could provide persistent improvements in dysregulated mineral metabolism, leading to a reduction in all-cause and cardiovascular (CV) mortality by reducing coronary artery calcium score (CACS) in refractory secondary hyperparathyroidism (SHPT). In this study, we have attempted to compare the effect of NPTX and cinacalcet therapy in patients with refractory SHPT on dialysis, with regard to their effects on CACS and FGF-23.
A total of 14 patients with refractory SHPT were followed prospectively. Five patients were enrolled in the NPTX arm and nine in the cinacalcet arm. Demographics, CACS, biochemical, and hormonal analysis were performed at baseline with a planned follow-up of 1 year.
The NPTX group showed a more favourable change in total calcification score over 1 year compared to the cinacalcet group, with a mean difference of 625.6 units. After NPTX, CACS was stable or reduced (<15% per year increase in CACS) in four of five (80%) patients. In the cinacalcet group, for those with a very severe baseline CACS (>400), there was a progression in the CACS. In the NPTX group, iPTH and FGF 23 reduced significantly after 1 year with an iPTH of 58.00 (8.5-76) pg/mL ( < 0.001) and FGF 23 of 5.4 (5.4-7.9) pg/mL ( < 0.04), respectively.
NTPTX resulted in amelioration of dysregulated mineral metabolism, leading to reduction or stabilization of CACS. There was also a marked reduction in FGF-23 levels following NPTX, which may be the principal factor in preventing the progression of CACS.
近全甲状旁腺切除术(NPTX)可使失调的矿物质代谢得到持续改善,通过降低难治性继发性甲状旁腺功能亢进(SHPT)患者的冠状动脉钙化评分(CACS),从而降低全因死亡率和心血管(CV)死亡率。在本研究中,我们试图比较NPTX和西那卡塞治疗对透析难治性SHPT患者的影响,以及它们对CACS和FGF-23的作用。
对14例难治性SHPT患者进行前瞻性随访。5例患者纳入NPTX组,9例纳入西那卡塞组。在基线时进行人口统计学、CACS、生化和激素分析,并计划随访1年。
与西那卡塞组相比,NPTX组在1年期间总钙化评分变化更有利,平均差异为625.6单位。NPTX后,5例患者中有4例(80%)的CACS稳定或降低(每年CACS增加<15%)。在西那卡塞组中,对于基线CACS非常高(>400)的患者,CACS有进展。在NPTX组中,1年后iPTH和FGF 23显著降低,iPTH为58.00(8.5 - 76)pg/mL(<0.001),FGF 23为5.4(5.4 - 7.9)pg/mL(<0.04)。
NTPTX改善了失调的矿物质代谢,导致CACS降低或稳定。NPTX后FGF-23水平也显著降低,这可能是防止CACS进展的主要因素。